KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Co-Diagnostics (CODX) Receivables (2018 - 2025)

Historic Receivables for Co-Diagnostics (CODX) over the last 8 years, with Q3 2025 value amounting to $55905.0.

  • Co-Diagnostics' Receivables fell 8546.57% to $55905.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $55905.0, marking a year-over-year decrease of 8546.57%. This contributed to the annual value of $242625.0 for FY2024, which is 5188.53% down from last year.
  • Co-Diagnostics' Receivables amounted to $55905.0 in Q3 2025, which was down 8546.57% from $210968.0 recorded in Q2 2025.
  • Over the past 5 years, Co-Diagnostics' Receivables peaked at $21.7 million during Q1 2022, and registered a low of $55905.0 during Q3 2025.
  • Its 5-year average for Receivables is $6.6 million, with a median of $4.2 million in 2023.
  • Its Receivables has fluctuated over the past 5 years, first surged by 100382.69% in 2021, then plummeted by 9230.4% in 2023.
  • Co-Diagnostics' Receivables (Quarter) stood at $20.8 million in 2021, then crashed by 68.56% to $6.6 million in 2022, then tumbled by 92.3% to $504264.0 in 2023, then tumbled by 51.89% to $242625.0 in 2024, then crashed by 76.96% to $55905.0 in 2025.
  • Its last three reported values are $55905.0 in Q3 2025, $210968.0 for Q2 2025, and $240805.0 during Q1 2025.